Biovelocita II attracts robust support from leading pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures The fund has already screened over 300 projects and made ...
A 5-year study of bimekizumab in ankylosing spondylitis encountered no new safety signals, with efficacy sustained even in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback